Table of Contents
Chemotherapy remains a cornerstone in the treatment of various cancers. Understanding the mechanisms of action of common agents helps in optimizing therapy and managing side effects.
Alkylating Agents
Alkylating agents work by adding alkyl groups to DNA molecules. This process causes cross-linking of DNA strands, which prevents DNA replication and transcription, ultimately leading to cell death. They are non-cell cycle specific, affecting both dividing and resting cells.
Antimetabolites
Antimetabolites interfere with DNA and RNA synthesis by mimicking natural metabolites. They inhibit enzymes involved in nucleotide synthesis, such as thymidylate synthase, or get incorporated into DNA/RNA, disrupting their function. Examples include methotrexate and 5-fluorouracil.
Topoisomerase Inhibitors
These agents inhibit topoisomerase enzymes, which are essential for DNA replication and transcription. Topoisomerase I inhibitors, like irinotecan, prevent the re-ligation of single-strand breaks, while topoisomerase II inhibitors, such as etoposide, block the re-ligation of double-strand breaks. This leads to DNA damage and apoptosis.
Mitotic Inhibitors
Mitotic inhibitors disrupt microtubule function, which is vital for cell division. Vinca alkaloids (e.g., vincristine) prevent microtubule polymerization, while taxanes (e.g., paclitaxel) stabilize microtubules, preventing their disassembly. Both actions halt mitosis and induce cell death.
Targeted Therapies
Targeted therapies are designed to interfere with specific molecules involved in cancer growth and progression. Examples include tyrosine kinase inhibitors like imatinib, which block signaling pathways, and monoclonal antibodies such as trastuzumab, which target specific cell surface receptors.
Conclusion
Understanding the mechanisms of action of chemotherapy agents enables clinicians to select appropriate treatments, predict potential side effects, and develop combination strategies for improved efficacy. Continuous research advances our knowledge, leading to more targeted and effective cancer therapies.